Patents Assigned to Oishi Koseido Co., Ltd.
-
Patent number: 11793766Abstract: [Problem] If lidocaine is composed of non-aqueous patch, the adhesive power of the preparation tends to get lower, as the composition amount of lidocaine is higher. It is popular to solve lidocaine in dissolving agent in order to compose lidocaine in patch and release effective amount into skin. However, if the amount of dissolving agent gets higher, the adhesive power gets extremely lower, so that an long-time attachment is difficult. [Solution] A non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent which are contained in a base of plaster, the plaster being hold by a support, of which strength of 50% stretched to longitudinal direction is less than 2000 g/50 mm and of biaxially-oriented stretch cloth.Type: GrantFiled: July 28, 2020Date of Patent: October 24, 2023Assignees: ITOCHU CHEMICAL FRONTIER Corporation;, OISHI KOSEIDO CO., LTD.Inventors: Tatsuya Mori, Naoyuki Saida
-
Patent number: 11786455Abstract: Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.Type: GrantFiled: February 8, 2022Date of Patent: October 17, 2023Assignees: ITOCHU CHEMICAL FRONTIER Corporation, OISHI KOSEIDO CO., LTD.Inventors: Tatsuya Mori, Naoyuki Saida
-
Patent number: 11278623Abstract: Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.Type: GrantFiled: July 28, 2020Date of Patent: March 22, 2022Assignees: ITOCHU CHEMICAL FRONTIER Corporation, OISHI KOSEIDO CO., LTD.Inventors: Tatsuya Mori, Naoyuki Saida
-
Patent number: 10765749Abstract: Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.Type: GrantFiled: February 8, 2018Date of Patent: September 8, 2020Assignees: ITOCHU CHEMICAL FRONTIER Corporation, OISHI KOSEIDO CO., LTD.Inventors: Tatsuya Mori, Naoyuki Saida
-
Patent number: 10765640Abstract: [Problem] If lidocaine is composed of non-aqueous patch, the adhesive power of the preparation tends to get lower, as the composition amount of lidocaine is higher. It is popular to solve lidocaine in dissolving agent in order to compose lidocaine in patch and release effective amount into skin. However, if the amount of dissolving agent gets higher, the adhesive power gets extremely lower, so that an long-time attachment is difficult. [Solution] A non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent which are contained in a base of plaster, the plaster being hold by a support, of which strength of 50% stretched to longitudinal direction is less than 2,000 g/50 mm and of biaxially-oriented stretch cloth.Type: GrantFiled: September 27, 2011Date of Patent: September 8, 2020Assignees: ITOCHU CHEMICAL FRONTIER Corporation, OISHI KOSEIDO CO., LTD.Inventors: Tatsuya Mori, Naoyuki Saida
-
Patent number: 9931403Abstract: Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.Type: GrantFiled: July 11, 2017Date of Patent: April 3, 2018Assignees: Itochu Chemical Frontier Corporation, Oishi Koseido Co., Ltd.Inventors: Tatsuya Mori, Naoyuki Saida
-
Patent number: 9925264Abstract: Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.Type: GrantFiled: March 9, 2016Date of Patent: March 27, 2018Assignees: Itochu Chemical Frontier Corporation, Oishi Koseido Co., Ltd.Inventors: Tatsuya Mori, Naoyuki Saida
-
Publication number: 20170304449Abstract: Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.Type: ApplicationFiled: July 11, 2017Publication date: October 26, 2017Applicants: ITOCHU CHEMICAL FRONTIER CORPORATION, OISHI KOSEIDO CO., LTD.Inventors: TATSUYA MORI, NAOYUKI SAIDA
-
Publication number: 20160184432Abstract: Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.Type: ApplicationFiled: March 9, 2016Publication date: June 30, 2016Applicants: Itochu Chemical Frontier Corporation, Oishi Koseido Co., Ltd.Inventors: Tatsuya Mori, Naoyuki Saida
-
Publication number: 20140356412Abstract: [Problem] If lidocaine is composed of non-aqueous patch, the adhesive power of the preparation tends to get lower, as the composition amount of lidocaine is higher. It is popular to solve lidocaine in dissolving agent in order to compose lidocaine in patch and release effective amount into skin. However, if the amount of dissolving agent gets higher, the adhesive power gets extremely lower, so that an long-time attachment is difficult. [Solution] A non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent which are contained in a base of plaster, the plaster being hold by a support, of which strength of 50% stretched to longitudinal direction is less than 2,000 g/50 mm and of biaxially-oriented stretch cloth.Type: ApplicationFiled: September 27, 2011Publication date: December 4, 2014Applicants: OISHI KOSEIDO CO., LTD., ITOCHU CHEMICAL FRONTIER CORPORATIONInventors: Tatsuya Mori, Naoyuki Saida
-
Publication number: 20140171509Abstract: Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.Type: ApplicationFiled: May 10, 2011Publication date: June 19, 2014Applicants: OISHI KOSEIDO CO., LTD., ITOCHU CHEMICAL FRONTIER CORPORATIONInventors: Tatsuya Mori, Naoyuki Saida
-
Patent number: 6054484Abstract: Disclosed are a clear aqueous solution of diclofenac sodium dissolved in a mixed solvent of a fatty acid dialkylolamide and water; an anti-inflammatory analgesic composition excellent in percutaneous absorption, which comprises the clear aqueous solution and a higher unsaturated aliphatic alcohol contained in the solution; and a self-adhesive cataplasm comprising a cataplasm base and the clear aqueous solution, polybutene and gelatin added in the base. The clear aqueous solution of diclofenac sodium contains, in particular, diclofenac sodium, a fatty acid dialkylolamide and water at a ratio falling within a hexagonal region formed by linking the points A, B, C, D, E and F in the figure.Type: GrantFiled: August 7, 1998Date of Patent: April 25, 2000Assignees: Tsumura & Co., Oishi Koseido Co., Ltd.Inventors: Takashi Sekine, Eiji Ogura, Shinichi Ota, Kazuyuki Ishikawa, Takaaki Matsumoto
-
Patent number: D693011Type: GrantFiled: August 28, 2012Date of Patent: November 5, 2013Assignee: Oishi Koseido Co., Ltd.Inventors: Tatsuya Mori, Naoyuki Saida
-
Patent number: D704342Type: GrantFiled: February 22, 2012Date of Patent: May 6, 2014Assignee: Oishi Koseido Co., Ltd.Inventors: Tatsuya Mori, Naoyuki Saida